These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Patterns of relapse as determined by Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231 [TBL] [Abstract][Full Text] [Related]
28. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. Horn T; Krönke M; Rauscher I; Haller B; Robu S; Wester HJ; Schottelius M; van Leeuwen FWB; van der Poel HG; Heck M; Gschwend JE; Weber W; Eiber M; Maurer T Eur Urol; 2019 Oct; 76(4):517-523. PubMed ID: 30987843 [TBL] [Abstract][Full Text] [Related]
29. Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. Deek MP; Yu C; Phillips R; Song DY; Deville C; Greco S; DeWeese TL; Antonarakis ES; Markowski M; Paller C; Denmeade S; Carducci M; Walsh PC; Pienta KJ; Eisenberger M; Tran PT Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):948-956. PubMed ID: 31419509 [TBL] [Abstract][Full Text] [Related]
30. Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancer. Fodor A; Lancia A; Ceci F; Picchio M; Hoyer M; Jereczek-Fossa BA; Ost P; Castellucci P; Incerti E; Di Muzio N; Ingrosso G World J Urol; 2019 Dec; 37(12):2607-2613. PubMed ID: 29752513 [TBL] [Abstract][Full Text] [Related]
31. Henkenberens C; VON Klot CA; Ross TL; Bengel FM; Wester HJ; Katja H; Christiansen H; Derlin T Anticancer Res; 2017 Mar; 37(3):1273-1279. PubMed ID: 28314292 [TBL] [Abstract][Full Text] [Related]
37. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure? Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322 [TBL] [Abstract][Full Text] [Related]
38. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121 [TBL] [Abstract][Full Text] [Related]
39. Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging. Meijer D; van Leeuwen PJ; Donswijk ML; Boellaard TN; Schoots IG; van der Poel HG; Hendrikse HN; Oprea-Lager DE; Vis AN BJU Int; 2022 Jan; 129(1):54-62. PubMed ID: 34028165 [TBL] [Abstract][Full Text] [Related]
40. Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence. Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]